Hypertensive myocardial fibrosis

Nephrology Dialysis Transplantation

Volumn 21, Issue 1, 2006, Pages 20-23

  Cuspidi, Cesare ^a,b   Ciulla, Michele ^a,b   Zanchetti, Alberto ^b,c  

^a Istituto di Medicina Interna   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Fibrosis; Hypertension; Left ventricular hypertrophy

Indexed keywords

ATENOLOL; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; HYDROCHLOROTHIAZIDE; LABETALOL; LISINOPRIL; LOSARTAN; NIFEDIPINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; ZOFENOPRIL;

ARTICLE; CLINICAL TRIAL; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY, NEEDLE; FEMALE; FIBROSIS; HEART FUNCTION TESTS; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 30344463305     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi237     Document Type: Article

References (30)

1. Frohlich ED, Apstein C, Chobanian AV et al. The heart in hypertension. N Engl J Med 1992; 327: 998-1008
2. Leonetti G, Cuspidi C. Heart and vascular changes in hypertension. J Hypertens 1995; 13 [Suppl 2]: S29-S34
3. Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A, on behalf of the APROS investigators. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: The Assessment of Prognostic Risk Observational Survey. J Hypertens 2002; 20: 1307-1314
4. Casale PN, Devereux RB, Milner M et al. Value of echocardiography assessment of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-178
5. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352
6. Weber KT. Cardioreparation in hypertensive heart disease. Hypertension 2001; 38 [Part 2]: 588-591
7. Diez J, Lopez B, Gonzales A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 2001; 16: 328-335
8. Gonzalez A, Lopez B, Diez J. Fibrosis in hypertensive heart disease role of the angiotensin-aldosterone system. Med Clin N Am 2004; 88: 83-97
9. Rossi MA. Connective tissue skeleton in the normal left ventricle and in hypertensive left ventricular hypertrophy and chronic chagasic myocarditis. Med Sci Monit 2001; 7: 820-832
10. Olivetti G, Melissari M, Balbi T et al. Myocite cellular hypertrophy is responsible for ventricular remodelling in the hypertrophic heart of middle aged individuals in the absence of heart failure. Cardiovasc Res 1994; 28: 1199-1208
11. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16: 1031-1041
12. Ciulla MM, Paliotti R, Hess DB et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10: 657-664
13. Amanuma S, Sekiguchi M, Ogasawara S, Honda M, Hosoda S. Biventricular endomyocardial biopsy findings in essential hypertension of graded severity. Postgrad Med J 1994; 70 [Suppl 1]: S67-71
14. Brilla C. Regression of myocardial fibrosis in hypertensive heart disease: Diverse effects of various antihypertensive drugs. Cardiovasc Res 2000; 46: 324-331
15. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-272
16. Campbell JE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol 1995; 27: 1545-1560
17. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341-348
18. Lopez B, Gonzalez A, Querejeta R, Diez J. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005; 23: 1445-1451
19. Querejeta R, Varo N, Lopez B et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729-1735
20. Diez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations and procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation 1995; 91: 1450-1456
21. Laviades C, Varo N, Fernandez I et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98; 535-540
22. Lopez B, Querejeta R, Varo N et al. Usefulness of serum carboxyterminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-291
23. Lindsay MM, Maxwell P, Dunn FG. TIMP-1. A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136-141
24. Ciulla MM, Paliotti R, Magrini F. Ultrasonic echoreflectivity of the heart a measure of fibrosis? Adv Exp Med Biol 1997; 432: 45-54
25. Perez JE, Miller JG, Barzilai B et al. Progress in quantitative ultrasonic characterization of myocardium: From the myocardium to bedside. J Am Soc Echo 1988; 1: 294-305
26. Picano E, Pelosi G, Marzilli M et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990; 81: 58-64
27. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393
28. Dahlof B, Zanchetti A, Diez J et al. for the REGAAL Study Investigators. Effect of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855-1864
29. Ciulla MM, Paliotti R, Esposito A et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis. Results of a randomized trial. Circulation 2004; 110: 552-557
30. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003